Retrophin Inc (OQ:RTRX)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 3721 Valley Centre Dr Ste 200
SAN DIEGO CA 92130-3330
Tel: N/A
IR: See website
Key People
Gary A. Lyons
Independent Chairman of the Board
Eric M. Dube
President, Chief Executive Officer, Director
Laura M. Clague
Chief Financial Officer, Senior Vice President
Elizabeth E. Reed
Senior Vice President, General Counsel and Corporate Secretary
William E. Rote
Senior Vice President and Head of Research and Development
Peter Heerma
Chief Commercial Officer
Noah L. Rosenberg
Chief Medical Officer
Business Overview
Retrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.
Financial Overview
For the nine months ended 30 September 2019, Retrophin Inc revenues increased 7% to $128.7M. Net loss increased 22% to $116.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling/General/Admin. Expense increase of 40% to $76.4M (expense), Research and development - Balancing val increase of 14% to $98.4M (expense).
Employees: 214 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $496.41M as of Sep 30, 2019
Annual revenue (TTM): $172.42M as of Sep 30, 2019
EBITDA (TTM): -$71.67M as of Sep 30, 2019
Net annual income (TTM): -$123.62M as of Sep 30, 2019
Free cash flow (TTM): -$72.74M as of Sep 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 42,958,401 as of Oct 29, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization